Role of Serum Regucalcin in Diagnosis of HCC Clinical Trial
Official title:
Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
| Verified date | June 2017 |
| Source | Mansoura University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
Although the diagnosis and therapy of HCC have being improved, the poor prognosis still
remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it
is important to detect the protein biomarkers which are associated with HCC tumor progression
and may be useful as potential diagnosis or therapeutic targets.
SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiļ¬ed
from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular
carcinoma associated antigens [4]
Serum antibody response to SMP30 in various patients using the methods of Western-blot and
ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in
the one with alpha-fetoprotein (AFP) negative
| Status | Recruiting |
| Enrollment | 96 |
| Est. completion date | December 30, 2017 |
| Est. primary completion date | December 30, 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy) 2. Adult patients 3. Both genders are eligible. 4. Informed consent obtained from subject or subject's legal representative Exclusion Criteria: 1. Patient with other malignancies. 2. Patients with advanced comorbidities except for renal failure. 3. Prior chemotherapy |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Oncology Center Mansoura University | Mansoura | Dakahlia |
| Lead Sponsor | Collaborator |
|---|---|
| Mansoura University |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | serum regucalcin in HCC patients | This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to: evaluate its potential role as biomarker in diagnosis. evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters. |
1-12-2016 to 1-12-2017 |